Xenon Pharmaceuticals (NASDAQ:XENE) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 6th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.04. On average, analysts expect Xenon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
XENE stock opened at $10.68 on Monday. Xenon Pharmaceuticals has a 12 month low of $2.10 and a 12 month high of $15.92. The firm has a market capitalization of $205.71 million, a P/E ratio of -6.21 and a beta of 1.20. The company has a quick ratio of 20.83, a current ratio of 20.83 and a debt-to-equity ratio of 0.41.
XENE has been the subject of several research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $16.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 10th. Stifel Nicolaus upped their price target on shares of Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. BidaskClub downgraded shares of Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Saturday, October 13th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $14.33.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.